Advances in public health, medicine, and technology since the mid-19th century have redefined what is considered “natural” for human beings.

Advances in epigenetic age estimation are now applied in actuarial science to try to make risk assessment more precise.

“Anti-aging” appears to be on the verge of adoption as a legitimate project of medical science and clinical labor and effort.

Pursuit of longevity has become both a biomedical frontier and a booming consumer enterprise.

Documenting one’s assessment of a patient’s physical appearance during a clinical encounter is regarded as a key element of a clinician’s overall judgment of a patient’s health.

This article argues that inequitable access to interventions capable of dramatically extending human lifespans would undermine individual and collective upkeep of civic virtue.

Companies offering epigenetic testing should be more transparent about these tests’ reliability and limitations.

Preventing and postponing dementia have been important projects of health care, but what should count as evidence of success is unclear.

Electronic health records can be hard for people with a range of disabilities to access, which demands ethical and legal attention.

Announcement that the AMA Journal of Ethics will cease publishing new content after December 2025.